Key points
- Loss from ordinary activities after tax decreased by 8.8% to $4,455,877
- Successful completion of HERACLES clinical trial for SOF-SKN
- Published significant paper in Nature Immunology
- Strengthened strategic partnerships and announced new data on Sofra technology
- Appointed Dr Olivier Laczka as CEO
Full summary
Noxopharm Ltd's preliminary financial report for the year ended June 2026 shows a loss from ordinary activities after tax of $4,455,877, a decrease of 8.8% from the previous year. The company conducted the HERACLES clinical trial for SOF-SKN, a novel drug candidate for chronic inflammatory diseases, with no relevant safety issues found. Noxopharm also published a paper in Nature Immunology detailing the Sofra platform's breakthrough science. The company announced new data showing the potential of Sofra technology in treating autoimmune diseases and cancer. Additionally, Noxopharm strengthened its strategic partnership with Hudson Institute of Medical Research and engaged a global clinical research organization in preparation for a pre-Investigational New Drug meeting with the US FDA.